Clinical Trials, Phase IV as Topic
"Clinical Trials, Phase IV as Topic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Planned post-marketing studies of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques that have been approved for general sale. These studies are often conducted to obtain additional data about the safety and efficacy of a product. This concept includes phase IV studies conducted in both the U.S. and in other countries.
| Descriptor ID |
D017327
|
| MeSH Number(s) |
E05.318.760.250.500.230 E05.337.800.200 N05.715.360.775.088.500.230 N06.850.520.450.250.250.230
|
| Concept/Terms |
Drug Evaluation, FDA Phase IV as Topic- Drug Evaluation, FDA Phase IV as Topic
- Evaluation Studies, FDA Phase 4 as Topic
- Drug Evaluation, FDA Phase 4 as Topic
- Evaluation Studies, FDA Phase IV as Topic
|
Below are MeSH descriptors whose meaning is more general than "Clinical Trials, Phase IV as Topic".
Below are MeSH descriptors whose meaning is more specific than "Clinical Trials, Phase IV as Topic".
This graph shows the total number of publications written about "Clinical Trials, Phase IV as Topic" by people in this website by year, and whether "Clinical Trials, Phase IV as Topic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2018 | 0 | 3 | 3 |
| 2019 | 1 | 2 | 3 |
| 2020 | 0 | 4 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Clinical Trials, Phase IV as Topic" by people in Profiles.
-
A SMARTTT approach to Treating Tobacco use disorder in persons with HIV (SMARTTT): Rationale and design for a hybrid type 1 effectiveness-implementation study. Contemp Clin Trials. 2021 11; 110:106379.
-
Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine. Drug Deliv Transl Res. 2021 08; 11(4):1309-1315.
-
Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval. Viruses. 2020 Dec 31; 13(1).
-
Postapproval Vaccine Safety Surveillance for COVID-19 Vaccines in the US. JAMA. 2020 Nov 17; 324(19):1937-1938.
-
Assessing the Safety of COVID-19 Vaccines: A Primer. Drug Saf. 2020 12; 43(12):1205-1210.
-
Impact of comprehensive molecular testing to reduce antibiotic use in community-acquired pneumonia (RADICAP): a randomised, controlled, phase IV clinical trial protocol. BMJ Open. 2020 08 20; 10(8):e038957.
-
Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Jun 05; 21(1):491.
-
Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial. Am Heart J. 2020 08; 226:49-59.
-
A limited number of medicines pragmatic trials had potential for waived informed consent following the 2016 CIOMS ethical guidelines. J Clin Epidemiol. 2019 10; 114:60-71.
-
Oxidized LDL upregulates macrophage DPP4 expression via TLR4/TRIF/CD36 pathways. EBioMedicine. 2019 Mar; 41:50-61.